Introduction
============

Amyotrophic lateral sclerosis (ALS) is the most common and severe form of motor neuron disease (MND), an heterogeneous group of disorders defined by prominent motor neuron (MN) degeneration ([@B221]; [@B210]). Recent evidence has challenged such traditional view of selective neuronal loss demonstrating widespread extra-motor involvement in ALS and implying that neuronal populations other than MNs may also be affected ([@B86]; [@B26]; [@B162]). Furthermore, an expanded clinical spectrum has now been recognized, as overlapping phenotypes with other neuromuscular disorders ([@B220]), including peripheral neuropathies, have been described ([@B204]; [@B20]; [@B223]). Although in clinical practice MNDs should be differentiated from other peripheral nervous system (PNS) disorders, sensory and autonomic neurons in the dorsal root ganglia (DRG) and lower MNs in the ventral horns share important challenges, as proper stability and functioning of their long projections throughout the body requires a protective environment and efficient communication between the central nervous system (CNS) and the outermost areas of these cells. Nonetheless, differences in morphology and function may confer different patterns of resistance or vulnerability to specific stressors.

The aim of this review is to dissect PNS involvement in ALS, analyzing the evidence from clinical and pathological data to genetics in order to provide novel pathophysiological insights and potential implication for therapeutic strategies.

Diagnostic Challenges in ALS and ALS-Mimics
===========================================

In the absence of pathognomonic diagnostic biomarkers, ALS diagnosis relies on clinical findings suggestive of selective upper, and lower MN (LMN) lesion and the exclusion of alternative causes ([@B150]). The wide clinical heterogeneity of the disease led to the development of several phenotypic classifications, mainly dependent on the distribution of UMN and LMN lesions. In patients presenting with isolated signs of LMN involvement (LMN Syndrome -- LMNS), the differential diagnosis may be more challenging since the primary disease target may be the cell soma, the axon and its myelin, the neuromuscular junction (NMJ) or the muscle ([@B213]; [@B83]; [@B174]). Such disorders not only share the motor unit as a common target of damage, but may be potentially underpinned by common pathogenic mechanisms. Within this context, ALS, with special reference to its restricted LMN phenotypes, such as flair legs and flail arm syndromes, shows high overlap in terms of clinical presentation, targets and mechanisms of damage with hereditary axonal neuropathies, such as axonal Charcot-Marie-Tooth neuropathy (CMT2) and distal hereditary motor neuropathy (dHMN) ([@B74]). Besides the different rate of progression and spreading, distinction between these disorders could be difficult especially in the early phase, as clinical and neurophysiologic studies may be strikingly similar and may not able to discern the primary lesion site. Nonetheless, a recent study supported the value of the electroneurographic split hand index has recently been suggested for distinguishing ALS from mimic disorders ([@B163]). Moreover, pes cavus, traditionally considered a distinguishing clinical sign of CMT, has also been anecdotally reported in ALS patients ([@B32]), and is estimated to be as high as 2% our case series (data not published). Notably, the percentage of misdiagnosis in degenerative LMNS has been reported to be as high as 19%; moreover, up to 10% of patients initially diagnosed as ALS are ultimately re-diagnosed as having another disease, including peripheral neuropathy ([@B48]; [@B241]; [@B251]). Therefore, in some cases, MND diagnosis remains uncertain, and only follow up can lead to a satisfying level of diagnostic confidence. Of note, we previously showed that biopsy of obturator nerve may be useful in the distinction between ALS and motor neuropathies ([@B39]; [@B213]). Signs of acute axonal damage, focal/multifocal fiber loss and absent or scarce axonal regeneration are consistently observed in motor nerve biopsies from patients with ALS ([Figure 1A](#F1){ref-type="fig"}), while neuropathies show a higher regeneration capacity and may present signs of myelin damage, inflammation, or pathologic deposits ([@B18]).

![Representative neuropathological cases. **(A)** Transverse semi-thin sections of motor nerve biopsy (obturator nerve), and sural sensory nerve biopsy **(B)** from a patients with MND. **(A)** Focal loss of myelinated nerve fibers is evident (asterisk) in the endoneurium together with signs of acute axonal degeneration (myelin ovoids, arrows); no signs of regeneration are observed. **(B)** In sural sensory nerve biopsies a diffuse mild reduction of large nerve fibers is observed. Bar: 20 μm.](fnins-13-00601-g001){#F1}

The PNS as a Converging Point in ALS
====================================

Evidence of Peripheral Nervous System Involvement in Human ALS
--------------------------------------------------------------

Although the circumstances leading to MN damage in ALS are still unknown, different mechanisms have been proposed to explain disease onset and spread. The dying-forward hypothesis states that the primary site of damage resides in the cell soma and subsequently spreads to the peripheral compartments. In the recent years, the dying-back pattern of degeneration has obtained a large attention in the context of ALS pathophysiology ([@B73]), suggesting that ALS is a distal axonopathy, a pattern typically seen in peripheral neuropathies with a distal to proximal gradient of damage ([@B63]). Therefore, considering that both motor and sensory nerves share mechanisms of axonal degeneration, it may be plausible that in ALS signs of PNS dysfunction may also extend to the sensory system. Notably, other neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease show evidence of distal axonopathy ([@B9]; [@B37]).

While diagnostic assessment in ALS relays on the assumption that non-motor components of the PNS are usually spared, increasing amount of evidence suggests the presence of sensory and autonomic dysfunction in ALS. Sensory symptoms are reported in about 2--30% of cases ([@B93]; [@B96]). Numbness, tingling and pain are the most common symptoms reported. Decreased vibration sense and abnormal pain and temperature thresholds are rarely observed during standard examination, however quantitative sensory testing shows abnormal findings in about 10% of patients, rising to almost half of the cases in advanced stages of the disease ([@B244]; [@B112]).

Autonomic dysfunction has been reported in 5--30% of cases, while quantitative autonomic testing detected abnormal sudomotor and cardiovagal response in up to 50% of patients ([@B162]; [@B196]). Abnormalities in either sensory nerve amplitudes or nerve conduction velocity may be apparent in about 20% of cases ([@B169]; [@B201]), with higher frequencies reported in patients with longer disease duration ([@B200]; [@B113]).

Pathologic studies of the sural nerve in ALS have demonstrated a mild reduction of the number of large nerve fibers ([Figure 1B](#F1){ref-type="fig"}) in most of the examined cases ([@B22]; [@B96]; [@B57]; [@B151]). Clustering of mitochondria, dilation of small vesicles and accumulation of neurofilaments (NF) have also been reported ([@B60]; [@B58]; [@B98]). Skin biopsy shows in about 80% of ALS patients a reduction of intraepidermal nerve fiber density ([@B263]; [@B244]; [@B45]; [@B186]) and focal axonal swellings, suggesting axonal degeneration ([@B112]). Interestingly, small nerve fibers in the cornea are also reduced in ALS patients, correlating with bulbar disability scores ([@B70]). Finally, a significant neuronal loss has been observed in DRG of ALS patients, with preferential involvement of large-sized cells ([@B125]). Notably, evidence of pTDP-43 pathology has been shown in Clarke's column, intermediolateral nucleus and dorsal root ganglia in a subset of cases, proving that these structures are also affected ([@B185]; [@B25]).

The Role of Genetics in ALS: At the Borders of the Disease Spectrum
-------------------------------------------------------------------

The knowledge about ALS genetics has had a relevant acceleration in the last decade, with more than 30 genes identified as pathogenic and more than 100 as ALS-related ([@B210]). The first gene identified as a cause of ALS was *SOD1* in 1993 ([@B214]) and together with *TARDBP* ([@B231]), *FUS* ([@B134]), and chromosome 9 open reading frame 72 (*C9orf72*) ([@B52]; [@B208]), represent the most common ALS-related genes, covering up to 70% of familial and 10% of sporadic cases ([@B210]; [@B34]). ALS-key genes have been associated with almost all clinical ALS phenotypes, although patients with SOD1, and FUS mutations may show preferential LMN involvement ([@B253]; [@B197]).

The frequency of gene variants in cases with extra-motor involvement is significantly higher compared to the pure ALS phenotype, and has been associated with poorer survival ([@B162]). Prominent sensory involvement had been described in rare mutated cases, with *SOD1* and *TARDBP* genes being reported most frequently ([@B28]).

Many of the genes involved in ALS are associated also with other neurological disorders sharing common targets of neurodegeneration, such as hereditary spastic paraplegia (HSP), axonal CMT neuropathy and dHMN. Among the genes involved in dHMN and axonal CMT there are Berardinelli-Seip Congenital Lipodystrophy 2 (*BSCL2*), neurofilament light (*NEFL*), transient receptor potential cation channel subfamily V member 4 (*TRPV4*), heat shock protein family B1, B3, and B8 (*HSPB1*, *HSPB3*, and *HSPB8)* ([@B156]; [@B215]). Despite the discrepancy between the major genes mutated in hereditary neuropathies and ALS, each of them exerts pleiotropic functions in neuronal homeostasis, including RNA metabolism, protein quality control, axonal transport, stress response. Therefore, generation of a spectrum of clinical phenotypes from alteration in master genes, broadly involved in key neuronal metabolic pathways, could be expected ([Table 1](#T1){ref-type="table"}).

###### 

Key genes associated with ALS, hereditary neuropathy, and overlapping phenotypes.

  Gene                 Gene name                                                          Chromosome   Disease^∗^                                                                                      Inheritance               References
  -------------------- ------------------------------------------------------------------ ------------ ----------------------------------------------------------------------------------------------- ------------------------- ---------------------------------------------------------------
  **ALS genes**                                                                                                                                                                                                                  
  C9orf72              Chromosome 9 open reading frame 72                                 9p21         FTD and/or ALS 1                                                                                AD                        [@B52]; [@B208]
  FUS                  FUS RNA Binding Protein                                            16p11        ALS6 with or without FTD                                                                        AD AR                     [@B245]
  OPTN                 Optineurin                                                         10p13        Open angle glaucoma -- ALS12                                                                    AD AR                     [@B209] (Glaucoma); [@B157] (ALS)
  PFN1                 Profilin 1                                                         17p13        ALS18                                                                                           AD                        [@B266]
  SOD1                 Superoxide dismutase 1                                             21q22        ALS1                                                                                            AD AR                     [@B214]
  SQSTM1               Sequestosome 1                                                     5q35         Paget disease of bone 3 -- FTD and/or ALS3                                                      AD                        [@B137] (Paget Disease); [@B68] (ALS)
  TARDBP               TAR DNA binding protein                                            1p36         ALS 10 with or without FTD                                                                      AD                        [@B90]; [@B121]
  UBQLN2               Ubiquilin 2                                                        Xp11.21      ALS15 with or without FTD                                                                       X-linked; AD              [@B55]
  **Overlap genes**                                                                                                                                                                                                              
  DCTN1                Dynactin subunit 1                                                 2p13         dHMNVIIB -- Perry syndrome -- ALS                                                               AD/AR Risk factor (ALS)   [@B202] (dHMN); [@B175] (ALS); [@B67] (Perry syndrome)
  DYNC1H1              Dynein cytoplasmic 1 heavy chain 1                                 14q32        CMT2O -- dSMA1 -- ALS                                                                           AD                        [@B176] (ALS); [@B260] (CMT); [@B97] (dSMA)
  FIG4                 FIG4 phosphoinositide 5-phosphatase                                6q21         CMT4J -- ALS11 -- Yunis-Varon syndrome                                                          AR -- AD                  [@B36], [@B35] (CMT, ALS); [@B30] (Yunis-Varon)
  GARS                 Glycyl-tRNA synthetase                                             7p15         CMT2D -- dHMNVA -- ALS                                                                          AD                        [@B6] (CMT -- dSMAV); [@B133] (ALS)
  KIF5A                Kinesin family member 5A                                           12q13        CMT2 -- SPG10 -- ALS25                                                                          AD                        [@B207]; [@B41] (HSP -- CMT2); [@B184] (ALS)
  MFN2                 Mitofusin 2                                                        1p36         CMT2A2A -- CMT2A2B -- dHMNVIA -- ALS like                                                       AD AR                     [@B273] (CMT2A2A); M[@B155] (ALS); [@B198] (CMT2A2B)
  NEFH                 Neurofilament heavy                                                22q12        ALS -- CMT2CC                                                                                   AD -- AR                  [@B71] (ALS); [@B206] (CMT)
  PLEKHG5              Pleckstrin homology and RhoGEF domain containing G5                1p36         CMTC; SMA -- SMA distal4 -- ALS                                                                 AR                        [@B161] (SMA); [@B16]; [@B128] (CMT); [@B189] (ALS)
  SETX                 Senataxin                                                          9q34         dHMN with pyramidal signs -- ALS4 juvenile -- spinocerebellar ataxia 1                          AD -- AR                  [@B50] (dHMN); [@B33] (ALS); [@B171] (spinocerebellar ataxia)
  SIGMAR1              Sigma non-opioid intracellular receptor 1                          9p13         ALS16 juvenile -- SMA distal 2                                                                  AR                        [@B5] (ALS); [@B141] (dSMA2)
  SPAST                Spastin                                                            2p22         SPG4 -- ALS juvenile                                                                            AD                        [@B80] (HSP); [@B165] (ALS)
  SPG11                Spatacsin vesicle trafficking associated                           15q21        SPG11 -- ALS5 juvenile -- CMT2X                                                                 AR                        [@B233] (SPG); [@B187] (ALS); [@B170] (CMT)
  VCP                  Valosin containing protein                                         9p13         IBMPFD- ALS14 with or without FTD -- CMT2Y                                                      AD                        [@B259] (IBMPFD); [@B118] (ALS); [@B91] (CMT)
  **CMT/dHMN genes**                                                                                                                                                                                                             
  BSCL2                BSCL2, seipin lipid droplet biogenesis associated                  11q13        Lipodystrophy, congenital generalized, type 2 -- dHMNVA -- silver spastic paraplegia syndrome   AR -- AD                  [@B152] (Lypodistrophy); [@B265] (dHMNVA, Silver syndrome)
  HSPB1                Heat shock protein family B (small) member 1                       7q11         CMT2F -- dHMN IIB                                                                               AD                        [@B64] (CMT dHMN)
  HSPB3                Heat shock protein family B (small) member 3                       5q11         dHMN IIC                                                                                        AD                        [@B131]
  HSPB8                Heat shock protein family B (small) member 8                       12q24        dHMN IIA -- CMT2L                                                                               AD                        [@B110] (dHMN); [@B239] (CMT)
  NEFL                 Neurofilament light                                                8q21         CMT2E -- CMT1F -- CMTG                                                                          AD AR                     [@B164] (CMT2E); [@B119] (CMT1F); [@B274] (CMT2G)
  TRPV4                Transient receptor potential cation channel subfamily V member 4   2q24         HMSN IIC -- SMA -- scapuloperoneal SMA                                                          AD                        [@B13]
                                                                                                                                                                                                                                 

∗

OMIM and report from literature. ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; CMT, charcot marie tooth; SMA, spinal muscular atrophy; SPG, spastic paraplegia; HMSN, hereditary motor and sensory neuropathy; Dhmn, distal hereditary motor neuropathy; UPS, ubiquitin proteasome system; ERAD, endoplasmic reticulum-associated protein degradation; IBMPFD, inclusion body myopathy paget disease frontotemporal dementia

.

Neurofilaments (NF) are composed of three subunits defined by their molecular weight and encoded by the NF light (*NEFL*), medium (*NEFM*), and heavy (*NEFH*) genes ([@B143]). NFs are specifically expressed in neurons and are the most abundant cytoskeletal components of myelinated axons, regulating their caliber, growth, and conduction rate ([@B105]). Mutations in *NEFL* are known to cause both axonal and demyelinating forms of CMT with different phenotypes, including pyramidal signs ([@B164]; [@B119]; [@B206]; [@B115]). Mutations in NEFH gene are involved in the pathogenesis of sporadic ALS ([@B71]; [@B4]) but also in CMT ([@B115]; [@B177]).

The cellular abundance of PI(3,5)P2, a phosphoinositide involved in the control of vesicles trafficking, is regulated by a phosphoinositide 5-phosphatase encoded by the *FIG4* gene. CMT4J cases, clinically characterized by early onset and aggressive disease progression, have been associated with by an autosomal dominant pattern of transmission and by biallelic *FIG4* mutations ([@B182]). Notably, heterozygous autosomal dominant *FIG4* variants have been more recently associated with ALS and identified as ALS11 ([@B188]).

The valosin containing protein (VCP) is member of the AAA ATPase family of proteins. This protein is ubiquitously expressed, and it is implicated in multiple cellular processes, such as cell survival ([@B246]; [@B23]), stress response and DNA and protein quality control ([@B54]; [@B120]; [@B262]). Mutations in *VCP* have been described in patients with autosomal dominant inclusion body myopathy (IBM) associated with Paget disease and fronto-temporal dementia (FTD) (IBMPFD) ([@B259]), pure ALS patients (Johnson et al., 2010; [@B166]), and recently also CMT ([@B91]; [@B117]).

The exact function of senataxin (SETX) is unknown but it may be involved in RNA metabolism. Studies have shown a role in DNA transcription and repair ([@B235]; [@B229]). Mutations in *STX* have been described in ataxia-ocular apraxia 2 (AOA2) ([@B171]; [@B59]; [@B79];[@B11]; [@B2]; [@B78]), autosomal dominant juvenile ALS ([@B33]; [@B271]; [@B15]; [@B10]; [@B243]), and in dHMN with pyramidal features ([@B50]).

The Spastic Paraplegia 11 gene (*SPG11*) encodes the spatacsin protein, selectively expressed in neuron with a role in axonal growth, transport, and cytoskeletal stability ([@B192]). *SPG11* variants were first described in patients with autosomal recessive spastic paraplegia 11 with thin corpus callosum ([@B100]). Then, descriptions in juvenile ALS (ALS5) and in CMT2X were also reported ([@B187]; [@B47]; [@B114]; [@B170]).

The dynactin subunit 1 (*DCTN1*) and kinesin family member 5A (*KIF5A*) genes encode for dynactin and kinesin subunits, involved in retrograde and anterograde axonal transport, respectively ([@B104]; [@B135]). *DCTN1* and *KIF5A* variants have been variably described in ALS ([@B176], [@B175]; [@B147], [@B146]; [@B24]; [@B184]), CMT, and dHMN ([@B41]; [@B149]).

Finally, pleckstrin homology and RhoGEF domain containing G5 (*PLEKHG5*) and mitofusin 2 (*MFN2*) genes, whose mutations are known to cause CMT ([@B173]; [@B273], [@B272]; [@B62]; [@B53]; [@B183]; [@B16]; [@B128]; [@B108]), have been also reported in patients with ALS or an "ALS-like" phenotype ([@B155]; [@B189]).

Pathogenic Mechanisms of PNS Damage in ALS
==========================================

Peripheral Motor and Sensory Dysfunction in ALS Models
------------------------------------------------------

The strongest evidence supporting the dying-back pattern of degeneration comes from transgenic mice overexpressing the mutated form of human SOD1 G93A (hSOD-1^G93A^), the most studied ALS model. Axonal pathology precedes spinal MN death and symptom onset, with the NMJ being the first site of morphological alteration ([@B73]). Along with disease progression, the burden of axonal pathology overcomes the moderate MN loss in spinal cord, and suggesting that the motor phenotype in these mice models is mainly driven by the PNS damage ([@B92]; [@B99]). Indeed, interventions leading to complete rescue of MNs in the spinal cord of mutant SOD1 (mSOD1) ALS mice were not sufficient to halt axonal loss and motor phenotype, suggesting that mechanisms of central, and peripheral degeneration may be at least partially independent ([@B92]; [@B217]; [@B236]).

Despite the wealth amount of data generated from this model about MN degeneration, important concerns remain about the reproducibility of these findings in human ALS. The preferential involvement of spinal compared to cortical MNs, the anatomical differences in CNS organization between mice and humans and the confounding effects of artificial manipulation, such as transgenic overexpression, limit the translation of ALS preclinical research on patients ([@B123]; [@B195]). Nonetheless, some studies reported evidence of early NMJ alterations and axonal injury preceding MN loss also in ALS patients ([@B22]; [@B56]; [@B73]; [@B27]). Moreover, progressive NMJ and motor axon loss is a consistent finding also in other transgenic ALS mice with mutations in *TARDBP*, *FUS*, and *C9orf72* repeat expansion ([@B197]). Overexpression of hTDP-43^A315T^ and hTDP-43^WT^ leads to NMJ denervation and loss of corticospinal axons, which in some cases predominate over MN al loss ([@B261]; [@B12]; [@B103]). In the hFUS^P525L^ mouse lines, where the mutation is conditionally expressed in MNs, the progressive degeneration is preceded by early pre-symptomatic retraction of motor axons ([@B227]).

Reflecting evidence of sensory dysfunction in human ALS, transgenic hSOD-1^G93A^ mice also display neurodegeneration in sensory axon, DRG and proprioceptive sensory fibers of muscle spindles. Signs of axonal damage are detected since the pre-symptomatic stage, progressing with a distal-to-proximal gradient ([@B95]; [@B247]). Furthermore, loss of dorsal root axons has been detected in rodent models overexpressing mutant TDP-43 and FUS ([@B107]; [@B12]), suggesting that ALS-specific proteins may also affect sensory neurons. However, it is still unclear whether the damage comes from nearby disease spreading or arise independently from MNs. Interestingly, transfection of mutant TDP-43 and SOD1 in cultured sensory neurons exert a negative impact on neurites length and arborization after prolonged culture, suggesting a direct effect ([@B248]).

Therefore, the reported evidence demonstrates that all components of the PNS are affected in ALS, although the differing kinetics of damage and progression still point to differences in vulnerability between the sensory and motor axons and neurons.

Unraveling Mechanisms of Vulnerability and Resistance of Peripheral Motor and Sensory Neurons in ALS
----------------------------------------------------------------------------------------------------

Studies addressing the mechanisms of PNS involvement in ALS may provide a unique opportunity for unraveling the determinants of the different patterns of vulnerability of motor and sensory neurons. This would allow the identification of specific protective or deleterious factors amenable of therapeutic intervention. Hereafter, we discuss key factors at the PNS level potentially implied in such differences.

### Intrinsic Axonal Vulnerability

Hyperexcitability of the axolemma, due to altered Na^+^ and K^+^ conductance properties, has been demonstrated in motor but not sensory axons of ALS patients ([@B228]; [@B190]; [@B158]). The consequent increase in Ca^2+^ influx may be selectively harmful in the motor compartment, since motor axons show a low Ca^2+^-buffering capacity ([@B116]; [@B138]). In turn, Ca^2+^ overload leads to the activation of effector proteins such as calpain, a calcium-dependent protease, involved in TDP-43 fragmentation, which predisposes to aggregation, Wallerian degeneration and NMJ disassembly ([@B267]; [@B38]; [@B29]). Specific demise of MNs may also be driven by the involvement of ALS-key proteins, such as TDP-43 and FUS. They are mRNA-binding proteins, mainly localized in the nucleus, which participate in the metabolism of broad pools of mRNAs, by affecting splicing, stability, transport. Mutations in these proteins affect neurons by both loss and gain of function, leading to altered RNA processing, increasing cytoplasmic translocation and propensity to aggregation ([@B205]). They are essential during embryonic development, but only MNs in the cortex and anterior horns display sustained expression of both proteins during lifetime ([@B106]). Although most of the transcriptome is shared between motor and DRG axons, more than one third is unique ([@B216]). It has been estimated that TDP43 binds roughly 30% of the whole transcriptome ([@B145]), including coding and non-coding RNAs, such as miRNA ([@B124]). TDP-43 is actively recruited in RNA granules along motor axons for active transport ([@B65]). Examples of TDP43-bound mRNAs include human neurofilaments, components of the endosomal trafficking and mitochondrial proteins ([@B232]; [@B226]; [@B257]). Over-expression of wild type and mutant TDP-43 alters the dynamics of its axonal transport ([@B3]), leading to mitochondrial toxicity and NMJ loss ([@B144]; [@B242]; [@B257]). Furthermore, a transient increase in TDP-43 localization along axonal routes is observed following axotomy, suggesting a role in peripheral nerve regeneration ([@B168]). However, TDP-43^G348C^ mice show abnormal persistence of cytoplasmic levels after peripheral injury, impairing axonal regeneration ([@B237]). Such finding may provide a potential additional explanation to the paucity of regenerative clusters observed in ventral roots and motor nerves of human and animal ALS ([@B213], [@B211]; [@B151]). In contrast, sensory nerves still show some level of regeneration capacity in ALS patients, suggesting that efficient repair mechanisms may dampen progressive neurodegeneration ([@B96]; [@B111]).

### Neuromuscular Junction

The early susceptibility of the NMJ in ALS relies on peculiar features that distinguish it from other peripheral ending structures, including the sensory receptors. It has high energy demands and requires efficient mechanisms of plasticity and repair to cope with the challenges faced by muscle contraction. Oxidative stress, which contributes to ALS pathogenesis ([@B46]), has a great influence on NMJ function, as the early production of reactive oxygen species (ROS) in distal muscles inhibits transmitter release ([@B132]; [@B180]) and leads to synaptic loss ([@B75], [@B76]). High levels of oxidative stress have also been observed in muscles and spinal cord of ALS patients ([@B46]; [@B136]). Mitochondrial dysfunction further participates to NMJ dismantling, as its role in energy production and Ca^2+^ buffering is essential for proper function and maintenance of the synapse ([@B77]). Non-neuronal factors are also involved, as terminal schwann cells (TSCs) exert important functions in NMJ stability and repair, adapting their state according to local synaptic environment. Such decoding ability depends on the muscarinic acetylcholine receptor (mAchR), a G-protein-coupled receptor (GPCR) present on the membrane of TSCs, which detects the level of Ach released in the synaptic cleft. SOD1 mutants have been shown to alter the mAchR sensitivity of these cells to local damage, leading to deficient repair of denervated NMJ in ALS mice models ([@B7]). Still, such findings need confirmation in humans and other models of ALS, although a relationship between TDP-43 function and TSC-related receptors has been suggested ([@B8]).

### PNS-Related Non-cell Autonomous Toxicity

Besides TSCs, other non-cell autonomous mechanisms in the PNS may further influence MNs vulnerability. The role of Schwann cells in the peripheral nerve has also been recently re-evaluated in ALS. Early deficits in axonal transport may be initially compensated by the transfer of polyribosomes from Schwann cells to the axonal compartment, boosting local protein synthesis as an adaptive response to mSOD1-induced injury ([@B249]). Moreover, Schwann cells may exert partial protection against the increased production of ROS related to axonal degeneration, as the loss of dismutase activity in these cells accelerated disease progression ([@B148]). However, pathogenic gain-of-functions SOD1 mutants may affect Schwann cells functioning and protective effects as well ([@B256]). Neuroinflammatory response within the PNS and alterations of the blood-nerve barrier might offer additional insights in the pathogenesis of ALS ([@B122]; [@B17]), as suggested by observations raised in mice models ([@B203]; [@B178], [@B179]) and in human ALS ([@B57]; [@B212]; [@B85]). Pathological studies of sural nerve biopsies of ALS patients have demonstrated, in a subset of cases, the presence of vasculitic-like inflammatory infiltrates associated with normal nerve morphology, suggesting a potential neuroprotective effect of neuroinflammation within the PNS ([@B57]). Indeed, the recruitment of macrophages and stimulation of their phagocytic function in peripheral nerves is important to create a favorable milieu for axonal regeneration, as shown in mSOD1 ALS mice ([@B178]).

Common Grounds for ALS and Hereditary Neuropathies
--------------------------------------------------

Despite the distinctive prognosis and disease course, ALS, related MNDs and hereditary neuropathies show a non-negligible degree of overlap in terms of both clinical presentations and genetics. Therefore, a better understanding of the key cellular pathways involved in both diseases may allow a broader comprehension of the molecular events leading to axonal and MN degeneration in ALS.

### Neuronal Cytoskeleton

Microtubules, NFs and actin are the main components of axonal cytoskeleton, and impairment in either structure or functioning of any of these components may lead to axonal atrophy, retraction and degeneration or transport defects ([@B84]; [@B126]). Elevated levels of light NFs (NFL) and phosphorylated heavy NFs have been observed in the cerebrospinal fluid and serum of ALS, together with lower mRNA NFL levels in MNs ([@B252]; [@B82]; [@B69]). Accumulation of NF components in axons is a prominent feature of both human and animal ALS ([@B140]; [@B218]; [@B172]), and has been observed along both motor and sensory axons in the hSOD-1^G93A^ ALS mouse model ([@B130]; [@B84]; [@B222]). Alterations of ALS-key genes, such as *SOD1* and *TARDBP*, have been shown to affect the stability of NFL mRNA, suggesting that altered stoichiometry between the different NF components may contribute to the disease ([@B252]). Mutations in *NEFL* and *NEFH*, leading to axonal CMT, promote protein aggregation, aberrant mitochondrial morphology and shortening of axonal length ([@B268]; [@B206]; [@B177]). Tubulin Alpha 4a (*TUBA4A)*, encoding for α-tubulin, has been recently identified as a novel ALS gene ([@B230]). It has been shown that *TUBA4A* mutations are able to alter microtubule dynamics, with depolymerization and degradation of α-tubulin ([@B101]). Although this gene has been described only in cohorts of ALS and FTD patients, a sensory and motor neuronopathy is observed in progressive motor neuronopathy mice mutated in tubulin binding cofactor E (*TBCE*), a known interactor of α-tubulin ([@B225]). Profilin 1 (*PFN1*) has been found as a rare cause of familial ALS ([@B266]). It is a crucial protein for the conversion of monomeric (G)-actin to filamentous (F)-actin. Interestingly, although pathogenic variants do not disrupt actin dynamics ([@B81]), alterations in microtubule growth and increased propensity to cytoplasmic TDP43 aggregation have been described ([@B159]; [@B238]; [@B102]), revealing potential cell-type specific mechanisms of neurodegeneration.

### Axonal Transport

Defects in axonal transport have been clearly observed both in ALS and dHMN. SOD1 and TDP43 mutants impair anterograde and retrograde axonal transport, leading to loss of essential synaptic components, mitochondrial abnormalities, and neurite shortening ([@B264]; [@B193]; [@B3]). Similarly abnormal transport of organelles, such as mitochondria and the endoplasmic reticulum (ER), is found in CMT models due to *NEFL* mutations ([@B240]). The failure of axon-cell body communication may dampen the activation of repair mechanisms, thus conferring an increase vulnerability of the peripheral compartment, more pronounced for the distal segments ([@B73]; [@B44]). Strategies aiming at reinforcing axonal transport may thus confer protection to a broad range of pathogenic alterations, preserving the axonal routes and its endings.

### Protein Folding

The highly differentiated and post-mitotic state of MNs exerts a relevant pressure over the protein quality control system of the cell, which is devoted to the correct folding, function and turnover of the whole proteome. HSPB1/27, HSPB8/22, and sigma non-opioid intracellular receptor 1 (SIGMAR1) are three chaperones with a significant expression levels in MNs ([@B160]). Mutations of the small heat shock proteins have been mostly associated with a dHMN or axonal CMT2 phenotype, while *SIGMAR1* gene variants have been reported also in rare ALS patients ([@B5]; [@B215]). HSPB1 mutants alter both its chaperone activity in NF organization and preservation of axonal stability ([@B64]; [@B1]). HSPB8 mutant mice develop a progressive motor neuropathy through specific neurite degeneration ([@B109]; [@B21]). In addition, alterations in TDP-43 expression, and associated splicing is observed in the muscles of these mice ([@B40]). Conversely, there is a significantly higher HSPB8 expression in surviving neurons in the hSOD-1^G93A^ mouse model of ALS ([@B43]). Finally, SIGMAR1, together with MFN2 and vesicle-associated membrane protein-associated protein B/C (VAPB), are able to modulate unfolded protein response (UPR) sensors, including protein kinase RNA-like endoplasmic reticulum kinase (PERK) ([@B181]).

### Mitochondrial/Associated Membranes (MAMs)

The ER and mitochondria have evolved complex sites of interactions, defined as mitochondrial/associated membranes (MAMs), which are important for essential cellular functions, such as calcium homeostasis, autophagy, regulation of mitochondrial dynamics, and axon survival ([@B89]). Both ALS and hereditary neuropathies display dysfunction in one or more of MAM components. A huge number of cellular proteins participate in MAMs, including MFN2 and VAPB, which act as tethering sites between the two organelles ([@B19]). VAPB mutants affect the interaction with the mitochondrial protein tyrosine phosphatase-interacting protein 51 (PTPIP5) ([@B49]; [@B51]). Interestingly, TDP43 and FUS mutants have been shown to decrease ER-mitochondria contacts by disrupting VAPB-PTPIP5 binding ([@B234]). MFN2 mutants alter other MAM functions, such as mitochondrial transport, fusion, and autophagosome assembly ([@B129]). Loss-of function mutations in *SIGMAR1* display decreased ER-mitochondria association, resulting in MN death, and axonal degeneration due to impaired retrograde transport ([@B19]; [@B258]).

Therapeutic Perspectives
========================

Due to the high similarity between these neuromuscular disorders and the intimate relationship observed in the molecular pathways involved, it may not be surprising if functional proteins involved in either of the two diseases may provide benefits on their respective counterpart.

Preservation of NMJ is an attractive target to delay muscle denervation and disability in ALS. A drug-screening platform in *C. elegans* and zebrafish models of ALS identified pimozide, an already approved neuroleptic, as a NMJ stabilizer by blocking T-type Ca^2+^ channels ([@B191]). Despite some benefits in neurophysiologic measures were reported in hSOD-1^G93A^ mice and human patients in the first report, one study assessing long-term effects showed warned caution, as worsening of survival and muscle function were observed in mutant SOD1, and TDP-43 mice models ([@B199]). Notably, an agonist antibody directed toward muscle-specific kinase (MuSK), a post-synaptic tyrosine kinase receptor essential for NMJ maintenance, preserved motor synapses, delayed muscle denervation and extended lifespan in hSOD-1^G93A^ ALS mice ([@B31]). The promising findings of this study still awaits confirmation and replication in other disease models.

Reinforcing the action of factors involved in axonal stability and transport may restore soma-axon communication, delaying NMJ loss and axonal degeneration. Pharmacological inhibition of histone deacetylase 6 (HDAC6), a known client protein of HSPB1, was able to increase the stability of microtubules, rescuing axonal loss, and improving outcome in a CMT2F mouse model with mutant HSPB1 ([@B61]). Interestingly, HDAC6 inhibition was also able to restore axonal transport defects in patient-derived MNs mutated in FUS ([@B94]). Pharmacologic agents targeting microtubule dynamics, such as noscapine and vinblastine, delayed disease onset and prolonged survival in hSOD-1^G93A^ mice, by reducing microtubule turnover ([@B66]).

Inhibition of p38/mitogen-associated protein kinase (MAPK) signaling in MNs was able to restore retrograde axonal transport defects *in vivo* ([@B87]), together with reduced microglia-induced neuroinflammation in the spinal cord ([@B127]; [@B269]; [@B139]). However, it is remarkable that no significant improvement was observed on the clinical phenotype ([@B87]), suggesting that inhibition of this pathway alone is not sufficient to fully rescue MN function.

Reducing ER stress through either a potentiation of the chaperone system or inhibition of stress-related factors may limit the production rate of misfolded proteins. Enhancing HSPB8 activity has been shown to be protective against accumulation of TDP43 aggregates in MNs ([@B42]; [@B219]), and to extend survival of hSOD-1^G93A^ mice ([@B14]). Trehalose, a chemical chaperone known to induce HSPB8, reduces ER stress levels and improve autophagy, delaying disease, and prolonging MN survival in a mouse model ([@B270]; [@B142]). Upon UPR activation, cells switch to a state of translational repression and stimulation of chaperones' synthesis, processes regulated by phosphorylation of the eukaryotic translation initiation factor 2A (eiF2α). Salubrinal and guanabenz, two eiF2α phosphatase inhibitors, protected against MN degeneration in ALS mice ([@B224];[@B255]), although one study reported that guanabenz accelerated disease progression in an ALS model ([@B250]).

Considering their importance in cell physiology, MAMs could represent an important target for therapy in ALS and may prove beneficial for a wide array of downstream signaling cascades relying upon these structures. An agonist of SIGMAR1 was shown to improve muscle activity and motor performance in pre-symptomatic hSOD-1^G93A^ ALS mice ([@B154]). Notably, overexpression of MFN2 prevented NMJ loss and delayed onset and progression in a murine model by raising calpastatin levels, a calpain inhibitor, essential for survival, and function of the NMJ ([@B254]).

Boosting axonal regeneration through either neuron- or Schwann-targeting factors may also be a valuable alternative strategy in order to preserve motor function ([@B88]). Studies modulating Neuregulin 1 activity, a neurotrophic factor involved in peripheral nerve development and regeneration, in murine hSOD-1^G93A^ ALS lead to increased re-innervation and MN survival ([@B153]; [@B167]). However, other approaches aimed at slowing Wallerian degeneration, such as the mutations in the Slowed Wallerian degeneration (Wld^S^) and Sterile Alpha and TIR Motif Containing 1 (Sarm1) proteins, gave only modest or no results in terms of progression and survival ([@B72]; [@B194]), suggesting that alternative mechanisms may underlie the axonal loss observed in ALS.

Conclusion
==========

Clinical and pathological studies in both human patients and rodent models suggest that the PNS is involved in ALS pathogenetic cascade. A better comprehension of the molecular events occurring into the PNS may prove essential for a better understanding of MND pathomechanisms and may pave the way to the discovery of novel therapeutic targets. Considering that in ALS neurodegeneration derives from the combination of several dysfunctional pathways, it might be possible that the development of combination therapies acting on multiple cascades located in both the central and the peripheral compartments may show synergistic neuroprotective effect in order to prevent axonal degeneration, MN cell death, und ultimately in prolonging patients' survival.
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